This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

2024 ASCO® Annual Meeting Insights Hub
H

ASCO® 2024 Summary: "The Best of Myeloma - Review of the Top 5 Abstracts"

By 2024 ASCO® Annual Meeting Insights Hub FEATURING Hamza Hashmi
By 2024 ASCO® Annual Meeting Insights Hub FEATURING Hamza Hashmi
532 views
July 1, 2024
1 Comment
Login to view comments. Click here to Login

Featured Video

16:51
Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison

Featured Video

37:21
Amgen Sponsorship

New Approval for Frontline Consolidation in Patients with CD19-posit…

Feat. J. Mccloskey

2024 ASCO® Annual Meeting Insights Hub: Summaries & Highlights Videos

19:41
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 H&N Cancer Highlights: Key Insights From Clinical Tri…

Feat. K. Kerrigan
24:36
2024 ASCO® Annual Meeting Insights Hub

ASCO 2024 Highlights: Insights From Key Abstracts on mBC

Feat. S. Aithal
15:07
2024 ASCO® Annual Meeting Insights Hub

Highlights of Recent Updates in CML: Impact on Practice

Feat. E. Atallah
View All

Related Content

AUTOPLAY
21:05
Louisville Hematology Highlights

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Feat. R. Gale
17:52
Indy Hematology Review

2024 Updates on Emerging & Current Treatment of Multiple Myeloma

Feat. K. Anderson
16:42
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "The Best of Myeloma - Highlights & Key T…

Feat. H. Hashmi
17:46
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Highlights in 1L MM - Quadruplet Therapies …

Feat. A. Jakubowiak
07:11
GRACE

CAR T-Cell vs. Bispecific Therapies for Blood Cancers: How Oncologis…

Feat. A. Goodman, A. Jeong, S. Rajeeve
19:08
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "Practice Changing Updates in MM, SMM and MGU…

Feat. R. Banerjee
09:51
i3 Health

MRD Testing in Leukemias: When Negativity Is a Positive Thing

Feat. N. S. Raje
24:23
MyCancerHaven

Will CAR-Ts and Bispecifics Will Replace HSCT in Myeloma?

Feat. R. Vij, S. Al Hadidi
24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray
13:15
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Quadruplets in NDMM - The More the Better?…

Feat. O. Landgren
36:10
Insights from 2024 EHA Annual Meeting

Highlights in Plasma Cell Disorders From ASCO® and EHA

Feat. S. Al Hadidi
28:20
Indy Hematology Review

Managing Newly Diagnosed MM in 2024

Feat. S. Usmani
19:24
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Updates on Managing Newly Diagnosed MM - In…

Feat. P. Richardson
35:27
Dana-Farber Cancer Institute

Advances in Multiple Myeloma 2024: From Bench to Bedside

Feat. K. Anderson
13:47
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "MRD2STOP Study - Discontinuation of Maint…

Feat. B. Derman
06:19
Insights from 2023 ASH Annual Meeting

Dara-KRd in NDMM Without ASCT: Final Analysis of a Ph2 Trial

Feat. B. Derman
20:23
SOHO Brazil 2024

When to Consider Bispecific and CAR-T Therapy in MM

Feat. N. S. Raje
05:35
Saurabh Chhabra

Bispecifics & CAR-Ts in MM: How to Choose and How to Sequence

26:46
Samer Al Hadidi

CAR-Ts Earlier in MyelomaTherapy?: What We Learned From the Recent F…

22:33
Integrity CE

Treatment Strategies for R/R MM After Frontline Anti-CD38 Therapy

Feat. S. Usmani, J. Hillengass